Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

Blue Cross commercial and BCN commercial Category: Authorizations/referrals, Pharmacy

Date posted: Sept. 18, 2025

Starting Jan. 1, we'll change how we cover Rinvoq, Rinvoq LQ and Skyrizi on our Custom Select Drug List

Effective Jan. 1, 2026, we'll no longer cover Rinvoq[®], Rinvoq[®] LQ and Skyrizi[®] for members with plans using our Custom Select Drug List. The covered alternatives are listed on the table below. If members fill a prescription for one of these drugs on or after Jan. 1, 2026, they'll be responsible for the full cost.

The drugs that won't be covered are listed with suggested alternatives that we do cover that have similar effectiveness, quality and safety. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.

We encourage members to discuss their treatment options with their health care providers based on indication.

Drugs that won't be covered	Common use or drug class	Covered alternatives
Rinvoq [®] and Rinvoq [®] LQ	Ankylosing spondylitis	Preferred: Enbrel®, Simlandi®, Simponi®, Xeljanz®/XR Nonpreferred: Cimzia®, Cosentyx®, Taltz®
	Atopic dermatitis	Preferred: Adbry®, Cibinqo®, Dupixent®
	Crohn's disease	Preferred: Simlandi [®] , Tremfya [®] , Yesintek [™]
		Nonpreferred: Cimzia®, Entyvio®
	Giant cell arteritis	Preferred: Tyenne®
	Non-radiographic axial spondyloarthritis	Nonpreferred: Cimzia®, Cosentyx®, Taltz®
	Polyarticular juvenile idiopathic arthritis	Preferred: Enbrel®, Simlandi®, Tyenne®, Xeljanz®
		Nonpreferred: Cimzia [®] , Kevzara [®] , Orencia [®]
	Psoriatic arthritis	Preferred: Enbrel [®] , Otezla [®] , Simlandi [®] , Simponi [®] , Tremfya [®] , Xeljanz [®] /XR, Yesintek [™]
		Nonpreferred: Cimzia®, Cosentyx®, Orencia®, Taltz®
	Rheumatoid arthritis	Preferred: Enbrel [®] , Simlandi [®] , Simponi [®] , Tyenne [®] , Xeljanz [®] /XR



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

Blue Cross commercial and BCN commercial Category: Authorizations/referrals, Pharmacy

Date posted: Sept. 18, 2025

Drugs that won't be covered	Common use or drug class	Covered alternatives
Skyrizi®		Nonpreferred: Cimzia®, Kevzara®, Kineret®, Olumiant®, Orencia®
	Ulcerative colitis	Preferred alternatives: Simlandi [®] , Simponi [®] , Tremfya [®] , Xeljanz [®] /XR, Yesintek [™]
		Nonpreferred alternatives: Entyvio®, Zeposia®
	Crohn's disease	Preferred: Simlandi [®] , Tremfya [®] , Yesintek [™]
		Nonpreferred: Cimzia®, Entyvio®
	Psoriasis	Preferred: Enbrel [®] , Otezla [®] , Simlandi [®] , Tremfya [®] , Yesintek [™]
		Nonpreferred: Cimzia®, Cosentyx®, Sotyktu®, Taltz®
	Psoriatic arthritis	Preferred: Enbrel [®] , Otezla [®] , Simlandi [®] , Simponi [®] , Tremfya [®] , Xeljanz [®] /XR, Yesintek [™]
		Nonpreferred: Cimzia [®] , Cosentyx [®] , Orencia [®] , Taltz [®]
	Ulcerative colitis	Preferred: Simlandi [®] , Simponi [®] , Tremfya [®] , Xeljanz [®] /XR, Yesintek [™]
		Nonpreferred: Entyvio®, Zeposia®

<u>Subscribe</u> to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.